Anders Månsson
Directeur Général chez Anders Månsson Business Development AB
Fortune : 48 178 $ au 30/06/2024
Profil
Anders Månsson is currently the Chief Executive Officer at Oncoinvent AS, RhoVac ApS, and the Chief Executive Officer & Director at Mr. Månsson Business Development AB.
He is also the Chairman at CanImGuide Therapeutics AB.
Previously, he served as the Chief Executive Officer at LIDDS AB, Vice President & Head-Global Business Development at LEO Pharma A, and held various director positions at EQL Pharma AB, Respiratorius AB, and Amniotics AB.
He received his undergraduate degree from the University of Lund and his MBA from Business School Lausanne.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
EQL PHARMA AB
0,03% | 31/03/2023 | 10 000 ( 0,03% ) | 48 178 $ | 30/06/2024 |
Postes actifs de Anders Månsson
| Sociétés | Poste | Début |
|---|---|---|
CanImGuide Therapeutics AB
 CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | Président | 01/06/2017 |
RhoVac ApS
 RhoVac ApS Pharmaceuticals: MajorHealth Technology Part of Chosa Oncology AB, RhoVac ApS is a Danish company that aims to prevent cancer recurrence and progression after primary tumor therapy. The company is based in Hørsholm, Denmark. The company's clinical phase II product, iCIP™ - Precision LiPlaCis® & DRP® with Breakthrough designation option, consists of LiPlaCis® and its Drug Response. Anders Månsson has been the CEO of the company since 2019. | Directeur Général | 02/09/2019 |
| Anders Månsson Business Development AB | Directeur Général | - |
Oncoinvent AS
 Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | Directeur Général | 01/09/2023 |
Anciens postes connus de Anders Månsson
| Sociétés | Poste | Fin |
|---|---|---|
| LIDDS AB | Directeur Général | 01/08/2023 |
| AMNIOTICS AB | Directeur Général | 01/01/2019 |
| EQL PHARMA AB | Président | 17/08/2022 |
LEO Pharma A/S
 LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Corporate Officer/Principal | 01/05/2017 |
| CHOSA ONCOLOGY AB | Directeur Général | - |
Formation de Anders Månsson
| University of Lund | Undergraduate Degree |
| Business School Lausanne | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
 | Health Technology |
| EQL PHARMA AB | Health Technology |
| AMNIOTICS AB | Health Technology |
| LIDDS AB | Health Technology |
| Entreprise privées | 6 |
|---|---|
LEO Pharma A/S
LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Health Technology |
CanImGuide Therapeutics AB
CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | Health Technology |
RhoVac AB
 RhoVac AB BiotechnologyHealth Technology RhoVac AB opertaes as biotechnology company that engages in the research and development of immunotherapy. The firm develops therapeutic cancer vaccines. Its main focus is the development of a drug with the potential to prevent or limit the metastasis of metastatic cancers. The company was founded by Bo Anders Ljungqvist, Per Thor Straten, and Mads Hald Andersen in November 2015 and is headquartered in Lund, Sweden. | Health Technology |
RhoVac ApS
RhoVac ApS Pharmaceuticals: MajorHealth Technology Part of Chosa Oncology AB, RhoVac ApS is a Danish company that aims to prevent cancer recurrence and progression after primary tumor therapy. The company is based in Hørsholm, Denmark. The company's clinical phase II product, iCIP™ - Precision LiPlaCis® & DRP® with Breakthrough designation option, consists of LiPlaCis® and its Drug Response. Anders Månsson has been the CEO of the company since 2019. | Health Technology |
| Anders Månsson Business Development AB | |
Oncoinvent AS
Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | Health Technology |
